The mechanisms that drive responses to PD-1-blocking immunotherapy in some but not all patients have been puzzling. A new study suggests that the balance of PD-1 expression levels between CD8+ T cells and Treg cells might provide an answer.
- Halil-Ibrahim Aksoylar
- Vassiliki A. Boussiotis
